Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG. The teams’ former medic, who is currently facing a fit-to-practise tribunal, paints a stark picture of the gold-medal factory across […]
